^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    bicalutamide

    i
    Other names: ICI 176334, ICI176,334-1, ICI176334, ICI-176334
    Company:
    Generic mfg.
    Drug class:
    Androgen receptor inhibitor
    Related drugs:
    2d
    DNMT1-DUOXA1 axis discovers a novel methylation-ferroptosis circuit in bicalutamide-resistant prostate cancer. (PubMed, Redox Biol)
    This study not only provides mechanistic insights into the role of DUOXA1 in bicalutamide resistance but also highlights the HIF1α-DNMT1-DUOXA1 axis as a critical regulator of resistance. Our work suggests potential therapeutic strategies to overcome resistance through epigenetic modulation and activation of DUOXA1, offering a novel perspective on the molecular mechanisms of bicalutamide resistance and paving the way for the development of improved treatment approaches for advanced prostate cancer.
    Journal
    |
    AR (Androgen receptor) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • DNMT1 (DNA methyltransferase 1)
    |
    bicalutamide
    4d
    INT22-09-01: A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P1, N=80, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR expression
    |
    bicalutamide
    11d
    Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer (clinicaltrials.gov)
    P2, N=108, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    MK-2206 • bicalutamide
    16d
    Penile metastasis from prostate adenocarcinoma: A case report and review of the literature. (PubMed, SAGE Open Med Case Rep)
    We report an 85-year-old male with a history of Gleason 4+3 acinar adenocarcinoma, managed conservatively with long-term bicalutamide monotherapy because of his clinical stability...Literature review highlights venous or lymphatic spread as probable pathways, with prognosis varying widely. This case underscores the importance of considering secondary malignancy in penile lesions, utilizing histopathology and immunohistochemistry for definitive diagnosis, and tailoring management to patient comorbidities and preferences to preserve quality of life.
    Journal
    |
    NKX2-1 (NK2 Homeobox 1) • CDX2 (Caudal Type Homeobox 2) • TP63 (Tumor protein 63)
    |
    bicalutamide
    19d
    DARE: An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment (clinicaltrials.gov)
    P=N/A, N=800, Not yet recruiting, Bayer
    New trial • Real-world evidence
    |
    Nubeqa (darolutamide) • bicalutamide
    27d
    Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Dec 2027 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • bicalutamide
    28d
    The prognostic value of the CALLY index in patients with metastatic hormone-sensitive prostate cancer. (PubMed, World J Urol)
    The CALLY index is an accessible and independent prognostic biomarker for OS and CRPC progression in mHSPC. Its integration into clinical assessment could enhance risk stratification and support personalized treatment planning, potentially improving long-term patient outcomes.
    Retrospective data • Journal
    |
    CRP (C-reactive protein)
    |
    bicalutamide
    1m
    The Impact of Tumor Microenvironmental Acidity on Bicalutamide Sensitivity in Prostate Cancer Cells. (PubMed, Prostate Cancer)
    The efficacy of bicalutamide in prostate cancer cells is significantly influenced by extracellular pH. The drug exerts stronger cytotoxic, antimigratory, and proapoptotic effects at physiological pH (7.4) compared with acidic conditions (6.8).
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • VEGFC (Vascular Endothelial Growth Factor C) • CDH2 (Cadherin 2) • SNAI1 (Snail Family Transcriptional Repressor 1) • ANXA5 (Annexin A5)
    |
    bicalutamide
    1m
    VA STARPORT: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (clinicaltrials.gov)
    P2/3, N=464, Recruiting, VA Office of Research and Development | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • prednisone • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    1m
    Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov)
    P3, N=2050, Active, not recruiting, NRG Oncology | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Nubeqa (darolutamide) • bicalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)
    1m
    2693-CL-2101: A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed by the Body in Men With Prostate Cancer (2024-520286-31-00)
    P1, N=56, Not yet recruiting, Astellas Pharma Global Development Inc.
    New P1 trial
    |
    Xtandi (enzalutamide) • bicalutamide • apalutamide